Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Joseph Sgouros
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, J. Sgouros wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Clinical Trial Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study. 2018

Karavasilis, Vasilios / Samantas, Epaminontas / Koliou, Georgia-Angeliki / Kalogera-Fountzila, Anna / Pentheroudakis, George / Varthalitis, Ioannis / Linardou, Helena / Rallis, Grigorios / Skondra, Maria / Papadopoulos, Georgios / Papatsibas, George / Sgouros, Joseph / Goudopoulou, Athina / Kalogeras, Konstantine T / Dervenis, Christos / Pectasides, Dimitrios / Fountzilas, George. ·Department of Medical Oncology, Papageorgiou Hospital, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. karavasv@auth.gr. · Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece. · Section of Biostatistics, Hellenic Cooperative Oncology Group, Athens, Greece. · Department of Radiology, AHEPA Hospital, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. · Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece. · Oncology Department, General Hospital of Chania, Crete, Greece. · First Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece. · Department of Medical Oncology, Papageorgiou Hospital, School of Health Sciences, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. · Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece. · Oncology Department, University General Hospital of Larissa, Larissa, Greece. · Department of Pharmacovigilance, Hellenic Cooperative Oncology Group, Athens, Greece. · Translational Research Section, Hellenic Cooperative Oncology Group, Athens, Greece. · Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece. · First Department of Surgery, General Hospital Konstantopouleio Agia Olga, Athens, Greece. · Aristotle University of Thessaloniki, Thessaloniki, Greece. ·Target Oncol · Pubmed #30488350.

ABSTRACT: BACKGROUND: The prognosis of patients with advanced pancreatic cancer is dismal, and there is a need for novel and effective treatments. OBJECTIVES: Tο determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of a novel gemcitabine (G) and temsirolimus (T) combination (phase I) and estimate the 6-month progression-free survival (PFS) in patients treated with the T + G combination (phase II). PATIENTS AND METHODS: Eligible patients with histologically confirmed inoperable or metastatic pancreatic carcinoma (MPC) were entered into the trial. G was given bi-weekly and T weekly in a 4-week cycle. The first dose level was set at G 800 mg/m RESULTS: Thirty patients were enrolled in the phase I component at the pre-planned six dose levels; one bilirubin DLT of grade III occurred at the first dose level. The MTD was established as the approved doses of both drugs. Fifty-five patients were entered into the phase II component. Median relative dose intensities administered in the first cycle were 0.75 for T and 0.99 for G. Grade 3-4 hematological toxicities were recorded in 87.3% of patients. The most common non-hematological adverse events were metabolic disorders (81.8%) followed by gastrointestinal disorders (63.6%). Median PFS was 2.69 months (95% CI 1.74-4.95) and median OS was 4.95 months (95% CI 3.54-6.85), while the 6-month PFS rate was 30.9%. CONCLUSIONS: Combination of G and T is feasible in patients with locally advanced or MPC with manageable side effects, but lacks clinical efficacy. The study was registered in the Australian New Zealand Clinical Trials Registry (ACTRN12611000643976).

2 Clinical Trial Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. 2012

Maraveyas, A / Waters, J / Roy, R / Fyfe, D / Propper, D / Lofts, F / Sgouros, J / Gardiner, E / Wedgwood, K / Ettelaie, C / Bozas, G. ·Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Cottingham, UK. Anthony.maraveyas@hey.nhs.uk ·Eur J Cancer · Pubmed #22100906.

ABSTRACT: BACKGROUND: Annualised figures show an up to 7-fold higher incidence of vascular thromboembolism (VTE) in patients with advanced pancreatic cancer (APC) compared to other common malignancies. Concurrent VTE has been shown to confer a worse overall prognosis in APC. METHODS: One hundred and twenty three APC patients were randomised to receive either gemcitabine 1000 mg/m(2) or the same with weight-adjusted dalteparin (WAD) for 12 weeks. Primary end-point was the reduction of all-type VTE during the study period. NCT00462852, ISRCTN: 76464767. FINDINGS: The incidence of all-type VTE during the WAD treatment period (<100 days from randomisation) was reduced from 23% to 3.4% (p = 0.002), with a risk ratio (RR)of 0.145, 95% confidence interval (CI) (0.035-0.612) and an 85% risk reduction. All-type VTE throughout the whole follow-up period was reduced from 28% to 12% (p = 0.039), RR = 0.419, 95% CI (0.187-0.935) and a 58% risk reduction. Lethal VTE <100 days was seen only in the control arm, 8.3% compared to 0% (p = 0.057), RR = 0.092, 95% CI (0.005-1.635). INTERPRETATION: Weight adjusted dalteparin used as primary prophylaxis for 12 weeks is safe and produces a highly significant reduction of all-type VTE during the prophylaxis period. The benefit is maintained after dalteparin withdrawal although decreases with time.